Protirelin
TRH, Thyrotropin-releasing hormone, Thyroliberin, TRF, pGlu-His-Pro-NH2
Protirelin is synthetic thyrotropin-releasing hormone, the smallest peptide hormone in human physiology at just three amino acids. It triggers release of thyrotropin and prolactin from the anterior pituitary. It was once widely used as a diagnostic test of the pituitary-thyroid axis, but sensitive thyrotropin assays made it largely obsolete, and it has been discontinued in the United States and United Kingdom.
Mechanism
Thyrotropin-releasing hormone is synthesised in the hypothalamic paraventricular nucleus and reaches the anterior pituitary through the portal circulation. It binds the TRH receptor 1, a class A G-protein-coupled receptor on thyrotrophs and lactotrophs, coupling through Gq/11 to activate phospholipase C. The resulting inositol trisphosphate mobilises intracellular calcium while diacylglycerol activates protein kinase C, and the combined signal drives exocytosis of thyroid-stimulating hormone and prolactin, alongside increased transcription of the thyrotropin beta subunit and of prolactin. Thyroid-stimulating hormone then acts on the thyroid to increase iodide uptake and thyroid hormone synthesis and release. Circulating triiodothyronine and thyroxine feed back negatively at both the pituitary and hypothalamic levels, and it is this feedback loop that gives the TRH test its diagnostic logic: in primary hypothyroidism the unrestrained thyrotroph gives an exaggerated response, whereas in thyrotoxicosis, or where thyroid hormone replacement is excessive, the response is flat.
Protirelin also has actions beyond the thyroid axis that have repeatedly tempted researchers. TRH and TRH receptors are widely distributed in the central nervous system, in the brainstem, spinal cord, limbic system and cortex, where TRH acts as a neuromodulator with arousal-promoting and analeptic effects in animal models, and modulates cholinergic and dopaminergic transmission. It stimulates growth hormone release in acromegaly, an abnormal response used diagnostically, and it also releases growth hormone in some patients with chronic renal failure or depression, though not in healthy subjects. Its structural minimalism, with both termini chemically blocked, is what allows a three-residue peptide to survive in plasma at all, but the five-minute half-life and poor blood-brain barrier penetration have defeated every attempt to exploit its central actions therapeutically.
What the research shows
The diagnostic pharmacology of protirelin is reproducible and well characterised: an intravenous bolus produces a thyrotropin peak at 20-30 minutes, with an exaggerated and prolonged response in primary hypothyroidism, a blunted or absent response in thyrotoxicosis and in over-replacement with thyroid hormone, and characteristic patterns that once helped distinguish pituitary from hypothalamic causes of central hypothyroidism. The paradoxical growth hormone rise in a large proportion of patients with acromegaly, and the paradoxical thyrotropin response in thyroid hormone resistance, remain genuine physiological observations, though the precise percentages usually quoted derive from product labelling that could not be verified in this audit. What removed the test from routine practice was not any failure of the peptide but the arrival of third-generation thyrotropin immunoassays sensitive enough to detect suppression directly, making dynamic testing unnecessary in almost all situations.
The therapeutic literature is a cautionary tale worth stating in full, because protirelin is sometimes marketed as a nootropic or neuroprotective peptide on the strength of it. Open-label reports in the early 1980s suggested short-term motor improvement in amyotrophic lateral sclerosis, and small uncontrolled studies continued to report benefit into the 1990s: one Italian series of 30 subjects described statistically significant improvement in 17 of 23 ALS patients. Controlled trials did not replicate this. The Mitsumoto double-blind crossover study of acute intravenous and chronic subcutaneous administration found no benefit at all despite subjective reports of improvement, an instructive illustration of why placebo control matters in neurodegenerative disease. Trials in spinocerebellar degeneration, spinal muscular atrophy, schizophrenia and depression have been similarly small and unconvincing; a transient antidepressant effect after intravenous TRH has been described in small studies but has never translated into a usable treatment, chiefly because of the five-minute half-life and poor central penetration. Taltirelin, a longer-acting TRH analogue, is approved in Japan for spinocerebellar degeneration, which is the only regulatory success anywhere in this family, and it is a different molecule with its own limited evidence base.
Evidence assessment
Mixed evidence
The tier reflects a genuine split. For its diagnostic use in pituitary-thyroid axis testing, protirelin held regulator-approved labelling for decades with consistent, reproducible dose-response data, which on its own would qualify as strong. For therapeutic applications, the controlled evidence is negative: the double-blind crossover trial in amyotrophic lateral sclerosis found no benefit from either acute intravenous or chronic subcutaneous administration. Note that the open-label literature reported the opposite, which is precisely the point. Grading therapeutic evidence honestly, mixed is the accurate overall assignment, and readers should not mistake diagnostic validity for treatment efficacy.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials Preclinical only
A clearly negative result, and an important one. Although some patients reported subjective improvement, statistical analysis showed no beneficial effect from either the acute or the chronic TRH protocol. This trial, together with subsequent controlled studies, closed down the enthusiasm generated by uncontrolled open-label reports in the early 1980s.
Low doses of TRH in amyotrophic lateral sclerosis and in other neurological diseases Preclinical only
Corrected during audit, because the draft described this paper as documenting negative or unconfirmed results when it in fact reported the opposite. The authors reported a statistically significant neurological improvement in 17 of the 23 ALS patients, with little or no effect in the remaining ALS patients or in those with other neurological diseases. The paper is included here precisely because it illustrates the pattern in this literature: small uncontrolled studies reporting benefit that the double-blind controlled trials did not reproduce.
Approved product labelling: protirelin (thyrotropin releasing hormone) injection Preclinical only
Cited as the source for the core diagnostic pharmacology commonly quoted for protirelin: a thyrotropin peak 20-30 minutes after a 500 microgram intravenous bolus, a plasma half-life of about 5 minutes, a concurrent prolactin rise, a paradoxical growth hormone rise in a substantial proportion of patients with acromegaly, transient adverse effects in a large minority of recipients, and rare pituitary apoplexy in patients with macroadenomas.
Safety
A large minority of recipients experience adverse effects after an intravenous dose, though these are typically brief and self-limiting: nausea, headache, facial flushing, a strong urge to urinate, an odd taste, light-headedness and abdominal discomfort. Transient changes in blood pressure are frequent and may go in either direction; marked hypertension, marked hypotension and syncope have all been reported, and the approved labelling contraindicated use where blood pressure fluctuation would be dangerous, including in patients with severe ischaemic heart disease or cerebrovascular disease.
The most serious documented risk is pituitary apoplexy requiring acute neurosurgical intervention, reported rarely in patients with pituitary macroadenomas, which is why imaging status matters before testing anyone with a suspected pituitary mass. Bronchospasm has been described in patients with asthma. Protirelin was always a supervised hospital diagnostic agent given with the patient supine and monitored. It is now discontinued in both the United States and the United Kingdom, so any material obtained is by definition outside the regulated supply chain, of unverified identity and purity. There is no evidence base whatever for self-administration, and the null results of the controlled therapeutic trials mean there is no plausible benefit to weigh against those risks.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Protirelin injection was formerly licensed by the MHRA for the TRH stimulation test and has been discontinued. It is not routinely available; sensitive third-generation thyrotropin assays have almost entirely replaced dynamic TRH testing in UK endocrine practice, with occasional residual use in specialist assessment of central hypothyroidism or thyroid hormone resistance via unlicensed supply. |
| United States | Previously approved by the FDA as an adjunct in the diagnostic assessment of thyroid function and of pituitary or hypothalamic dysfunction, marketed as a 500 microgram per millilitre injection. It has been discontinued in the United States and is no longer commercially available. No therapeutic indication was ever approved. |
| WADA (sport) | Not explicitly named on the current WADA Prohibited List. Protirelin releases thyrotropin and prolactin rather than growth hormone or corticotropin in healthy subjects, so it does not fall within S2.2 (growth hormone secretagogues) or S2.4 (corticotrophins and their releasing factors). Athletes should nonetheless declare any use, since thyroid axis manipulation attracts scrutiny and the List is revised annually. |
Questions
Because the assay technology overtook it. Dynamic TRH stimulation testing was needed when thyrotropin assays could not reliably distinguish a low-normal value from a fully suppressed one. Third-generation thyrotropin immunoassays measure suppression directly, so the information the test used to provide is now available from a single blood sample. Protirelin was discontinued commercially rather than withdrawn for safety reasons.
No, on the controlled evidence. TRH has genuine arousal-promoting and neuromodulatory actions in animal models, and open-label reports in amyotrophic lateral sclerosis generated real excitement, with small uncontrolled series reporting improvement in most patients treated. Double-blind controlled trials, including acute intravenous and chronic subcutaneous protocols, showed no benefit despite patients reporting subjective improvement. That gap between uncontrolled and controlled results is the whole story here. Its five-minute half-life and poor blood-brain barrier penetration make sustained central effects difficult to achieve.
Thyrotropin-releasing hormone, at three amino acids. Its survival in plasma depends entirely on chemical blocking at both ends: an N-terminal pyroglutamate ring and a C-terminal amide, which together prevent exopeptidases from trimming it. Both modifications are also required for receptor binding, so the molecule is about as pared-down as a peptide hormone can be.
It is not explicitly named on the current WADA Prohibited List. It releases thyrotropin and prolactin rather than growth hormone or corticotropin in healthy people, so it does not fall under the S2.2 growth hormone secretagogue or S2.4 corticotrophin categories. The List is revised annually, and athletes should declare any use given the general scrutiny applied to thyroid axis manipulation.